Proferrin-ES and Tarceva

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Talk to your doctor before using erlotinib together with raNITIdine. RaNITIdine can interfere with the absorption of erlotinib and reduce its effectiveness if they are taken too close together. In some cases, your doctor may want to prescribe alternatives that do not interact. Otherwise, you may be able to minimize the interaction by taking erlotinib at least 2 hours before or 10 hours after raNITIdine. Contact your doctor if your condition worsens during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: Concurrent administration of agents that increase gastric pH such as H2-receptor antagonists may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption. When coadministered with ranitidine 300 mg, erlotinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 54% and 33%, respectively. Increasing the dose of erlotinib is unlikely to compensate for this loss of systemic exposure. In contrast, administration of erlotinib with ranitidine 150 mg twice daily in a staggered manner (at least 10 hours after the previous ranitidine evening dose and 2 hours before the ranitidine morning dose) resulted in reductions of erlotinib Cmax and AUC by just 17% and 15%, respectively.

MANAGEMENT: In general, the concomitant use of erlotinib with agents that increase gastric pH should be avoided whenever possible. If acid-suppression therapy is required during erlotinib treatment, an H2-receptor antagonist such as ranitidine may be considered. Available pharmacokinetic data suggest that erlotinib should be administered once a day, at least 2 hours before or 10 hours after dosing of the H2-receptor antagonist. Additionally, the lowest effective dosage of the H2-receptor antagonist should be prescribed. It may be appropriate to avoid using cimetidine for long-term acid suppression, as it may inhibit the CYP450 3A4-mediated metabolism of erlotinib and increase the risk of toxicity. However, clinical and pharmacokinetic data are lacking.

Proferrin-ES

Generic Name: heme iron polypeptide

Brand name: Proferrin-ES, Baciguent, Probiotic Formula

Synonyms: n.a.

What is Proferrin-ES?

Tarceva

Generic Name: erlotinib

Brand name: Tarceva

Synonyms: n.a.

What is Tarceva?